Compare BIO-TECHNE Corp (TECH) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? BIO-TECHNE Corp trades at $72.13 (market cap $11.24B), while Direxion Daily FTSE China Bull 3x Shares trades at $30.2. The key difference: BIO-TECHNE Corp pays a 0.44% dividend while Direxion Daily FTSE China Bull 3x Shares pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals.
| TECH | YINN | |
|---|---|---|
Market Cap | $11.24B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $72.29 | $56.62 |
52-Week Low | $43.31 | $21.45 |
Enterprise Value | $11.32B | — |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
YINN (Direxion Daily FTSE China Bull 3x ETF) trades at $31.50, up 1.68% with a bullish technical signal. The ETF tracks Chinese equities, showing strength amid Hang Seng Index outperformance versus Asian peers. Moving averages signal bullish momentum while oscillators remain neutral. Recent news highlights China's AI investment plans and export growth, though regulatory tensions with the US persist.
Outlook remains cautiously optimistic given China's tech focus and infrastructure spending, but leveraged structure amplifies risks. Key risks include US-China trade tensions and China's economic stabilization efforts. Investors should weigh the ETF's 3x leverage against China's growth trajectory and regulatory environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
